Investors Alerted to Securities Class Action Against Kyverna Therapeutics, Inc.
Kessler Topaz Meltzer & Check, LLP files securities class action lawsuit against Kyverna Therapeutics, Inc. for alleged false statements in IPO. Investors urged to act before February 7, 2025 deadline.
This news matters as it highlights potential misconduct by Kyverna Therapeutics, Inc. that may have led to investor losses. Investors who purchased Kyverna stock during its IPO should take note of the lawsuit and consider their options before the lead plaintiff deadline on February 7, 2025.
